Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients (Q37611687)

From Wikidata

Jump to navigation Jump to search

scientific article published on 03 October 2012

Language	Label	Description	Also known as
English	Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients	scientific article published on 03 October 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients (English)

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Bernard Vrijens

object named as

B Vrijens

8

0 references

author name string

R M Savic

1

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

A Barrail-Tran

2

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

X Duval

3

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

G Nembot

4

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

X Panhard

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

D Descamps

6

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

C Verstuyft

7

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

A-M Taburet

9

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

C Goujard

10

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

F Mentré

11

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ANRS 134–COPHAR 3 Study Group

12

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

language of work or name

0 references

publication date

3 October 2012

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

92

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

5

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

575-583

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Risk factors for gastrointestinal adverse events in HIV treated and untreated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

The odds that clinically unrecognized poor or partial adherence confuses population pharmacokinetic/pharmacodynamic analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Atazanavir: a novel HIV-1 protease inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

23 August 2017

Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

6 September 2017

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

25 June 2018

Comparing compliance patterns between randomized treatments.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

25 June 2018

A population pharmacokinetic-pharmacogenetic analysis of atazanavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Modelling the association between adherence and viral load in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

The impact of compliance in pharmacokinetic studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3939416

1 September 2018

Chronobiology. Suggestions for integrating it into drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/23033116

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/CLPT.2012.137

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37611687&oldid=2133323248"